Advertisement

Topics

NeoImmuneTech Company Profile

23:50 EDT 24th September 2018 | BioPortfolio

NeoImmuneTech, a Genexine related company founded in 2014, is focused on leading the development efforts for its flagship immunotherapy product, HyLeukin-7, in the US and EU. Based in Rockville, Maryland, NeoImmuneTech has the core competency of global clinical and business development with a strong scientific focus and a broad network of global leading R&D organizations. NeoImmuneTech is currently conducting Phase 1b/2a clinical trials of HyLeukin-7, aiming at developing not only the first-in-class treatment of lymphopenia but also a breakthrough cancer immunotherapy.


News Articles [6 Associated News Articles listed on BioPortfolio]

NeoImmuneTech to conduct HyLeukin-7 and Tecentriq Phase Ib/IIa trial

NeoImmuneTech (NIT), along with its parent company Genexine, has signed an agreement with Roche to perform a Phase Ib/IIa immuno-oncology...Read More... The post NeoImmuneTech to conduct HyLeukin-7 an...

NeoImmuneTech starts new trial of HyLeukin-7 for cancer

NeoImmuneTech has commenced its first clinical trial in the US to evaluate HyLeukin-7 for the treatment of cancer. The trial...Read More... The post NeoImmuneTech starts new trial of HyLeukin-7 for ca...

Roche and NeoImmuneTech to test combination therapy in skin cancers

Roche agreed to conduct a combination study of its Tecentriq (atezolizumab) with NeoImmuneTech Inc.’s HyLeukin-7 (IL-7-hyFc) in three high-risk skin cancers: melanoma, Merkel cell carcinoma, and cut...

NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S.

NeoImmuneTech, Inc. (NeoImmuneTech), an immunotherapy drug development company focused on advanced cancer treatments, announced today the initiation of its first U.S. clin...

NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers

NeoImmuneTech (NIT), an immunotherapy drug development company focused on advanced cancer treatments, and its parent company Genexine, have entered into an agreement with ...

Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for Combination Trial with Merck’s KEYTRUDA®

Genexine, a clinical stage biotechnology company developing innovative biologics, and its spin-off company in the US, NeoImmuneTech, Inc. (NIT), today announced that Hyleukin-7, t...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

NeoImmuneTech

NeoImmuneTech, a Genexine related company founded in 2014, is focused on leading the development efforts for its flagship immunotherapy product, HyLeukin-7, in the US and EU. Base...

More Information about "NeoImmuneTech" on BioPortfolio

We have published hundreds of NeoImmuneTech news stories on BioPortfolio along with dozens of NeoImmuneTech Clinical Trials and PubMed Articles about NeoImmuneTech for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NeoImmuneTech Companies in our database. You can also find out about relevant NeoImmuneTech Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record